Trial Profile
Discontinuation of long-term effective entecavir or tenofovir therapy in patients with HBeAg-negative chronic hepatitis B
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Dec 2018
Price :
$35
*
At a glance
- Drugs Entecavir (Primary) ; Tenofovir disoproxil fumarate (Primary)
- Indications Hepatitis B
- Focus Adverse reactions; Therapeutic Use
- Acronyms DARING-B
- 13 Nov 2018 Results (n=58) assessing the kinetics of serum HBcrAg in non-cirrhotic Chronic Hepatitis B patients who discontinued long-term effective ETV/TDF therapy, presented at The Liver Meeting 2018: 69th Annual Meeting of the American Association for the Study of Liver Diseases.
- 13 Nov 2018 Results examining predictors of HBsAg loss and retreatment in non-cirrhotic Chronic Hepatitis B patients who discontinued long-term effective ETV/TDF therapy, presented at The Liver Meeting 2018: 69th Annual Meeting of the American Association for the Study of Liver Diseases.
- 14 Apr 2018 Results presented at The International Liver Congress 2018